Susquehanna International Group
KRYS icon

Susquehanna International Group’s Krystal Biotech KRYS Stock Holding History

Susquehanna International Group’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.34M Buy
9,042
+7,175
+384% +$1.91M ﹤0.01% 5811
2025
Q4 		$460K Buy
+1,867
New +$393K ﹤0.01% 8984
2025
Q3 		– Sell
-30,252
Closed -$4.53M – 13211
2025
Q2 		$4.16M Sell
30,252
-3,577
-11% -$525K ﹤0.01% 4323
2025
Q1 		$6.1M Sell
33,829
-4,639
-12% -$780K ﹤0.01% 3285
2024
Q4 		$6.03M Buy
38,468
+28,914
+303% +$5.13M ﹤0.01% 3326
2024
Q3 		$1.74M Buy
9,554
+4,070
+74% +$785K ﹤0.01% 5562
2024
Q2 		$1.01M Sell
5,484
-96,073
-95% -$16.1M ﹤0.01% 6578
2024
Q1 		$18.1M Buy
101,557
+93,515
+1,163% +$13M ﹤0.01% 1895
2023
Q4 		$998K Buy
8,042
+898
+13% +$99.6K ﹤0.01% 7002
2023
Q3 		$829K Buy
7,144
+762
+12% +$93K ﹤0.01% 7070
2023
Q2 		$749K Sell
6,382
-19,737
-76% -$2.02M ﹤0.01% 7355
2023
Q1 		$2.09M Buy
26,119
+17,927
+219% +$1.41M ﹤0.01% 5034
2022
Q4 		$649K Sell
8,192
-12,058
-60% -$895K ﹤0.01% 7201
2022
Q3 		$1.41M Buy
20,250
+3,999
+25% +$289K ﹤0.01% 5739
2022
Q2 		$1.07M Buy
16,251
+1,138
+8% +$70.8K ﹤0.01% 6368
2022
Q1 		$1.01M Buy
15,113
+1,629
+12% +$102K ﹤0.01% 7102
2021
Q4 		$943K Buy
13,484
+1,028
+8% +$59.8K ﹤0.01% 7465
2021
Q3 		$650K Buy
12,456
+4,855
+64% +$287K ﹤0.01% 8710
2021
Q2 		$517K Sell
7,601
-2,876
-27% -$201K ﹤0.01% 9500
2021
Q1 		$807K Sell
10,477
-11,726
-53% -$853K ﹤0.01% 8282
2020
Q4 		$1.33M Buy
22,203
+9,925
+81% +$496K ﹤0.01% 6018
2020
Q3 		$529K Sell
12,278
-5,554
-31% -$241K ﹤0.01% 7546
2020
Q2 		$739K Buy
17,832
+11,293
+173% +$543K ﹤0.01% 6551
2020
Q1 		$283K Buy
+6,539
New +$342K ﹤0.01% 8090
2019
Q4 		– Sell
-6,630
Closed -$230K – 10203
2019
Q3 		$230K Buy
6,630
+416
+7% +$18.6K ﹤0.01% 8831
2019
Q2 		$250K Sell
6,214
-39,279
-86% -$1.28M ﹤0.01% 8673
2019
Q1 		$1.5M Buy
45,493
+26,796
+143% +$632K ﹤0.01% 4244
2018
Q4 		$389K Buy
+18,697
New +$391K ﹤0.01% 6516

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group's KRYS Position: Q1 2026 in Review

Susquehanna International Group increased its Krystal Biotech (KRYS) stake by 384% in Q1 2026, buying an estimated $1.91M and bringing the position to 9,042 shares worth $2.34M. The position accounts for ﹤0.01% of the portfolio, ranked #5811.

Susquehanna International Group first reported a position in KRYS in Q4 2018 and has held it in 28 quarters since. The position peaked at $18.1M in Q1 2024. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Susquehanna International Group held 9,042 shares of Krystal Biotech worth $2.34M as of Q1 2026.
  • Susquehanna International Group bought 7,175 Krystal Biotech shares in Q1 2026, an estimated $1.91M.
  • Krystal Biotech made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #5811 holding.
  • Susquehanna International Group first reported a position in Krystal Biotech in Q4 2018 and has held it in 28 quarters since.
  • Susquehanna International Group's Krystal Biotech position peaked at $18.1M in Q1 2024.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.